GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors (2000)
    Springer
    Annals of oncology 11 (2000), S. 17-22 
    Details
    ISSN: 1569-8041
    Keywords: breast cancer ; hot flashes ; paroxetine ; serotonin uptake inhibitors ; survivors
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:Many breast cancer survivors suffer debilitating hotflashes. Estrogen, the drug of choice in perimenopausal women, is generallynot recommenced to breast cancer survivors. Nonhormonal treatments are mostlydisappointing. Anecdotal reports in our institution suggested that theselective serotonin-reuptake inhibitor, paroxetine hydrochloride, might beefficacious in alleviating hot flashes. Patients and methods:Thirty women with prior breast cancer whowere suffering at least two hot flashes a day entered a single institutionpilot trial to evaluate paroxetine's efficacy in reducing the frequency andseverity of hot flashes. After completing daily diaries for one week on notherapy, the women received open-label paroxetine, 10 mg daily for one week,followed by four weeks of paroxetine, 20 mg daily. The women completedhot-flash daily diaries throughout the study period, and a health-relatedsymptom-assessment questionnaire and a quality-of-life rating scale in thefirst and sixth week of the study. Results:Twenty-seven women completed the six-week study period.The mean reduction of hot flash frequency was 67% (95%confidence interval (95% CI): 56%–79%). The meanreduction in hot flash severity score was 75% (95% CI:66%–85%). There was a statistically significantimprovement in depression, sleep, anxiety, and quality of life scores.Furthermore, 25 (83%) of the study participants chose to continueparoxetine therapy at the end of study. The most common adverse effect wassomnolence, resulting in drug discontinuation in two women, and dose reductionin two women. One woman discontinued drug due to anxiety. Conclusions:Paroxetine hydrochloride is a promising new treatmentfor hot flashes in breast cancer survivors, and warrants further evaluationin a double-blind randomized placebo-controlled trial.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008382706068
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Is permanent pacing for dilated cardiomyopathy and congestive heart failure a viable therapeutic option? (1999)
    Springer
    Herzschrittmachertherapie & Elektrophysiologie 10 (1999), S. 7-15 
    Details
    ISSN: 1435-1544
    Keywords: Schlüsselwörter Dilatative Kardiomyopathie ; dekompensierte ; Herzinsuffizienz ; permanentes Pacing ; Zweikammer-Pacing ; Schrittmacher-Hämodynamik ; Key words Dilated cardiomyopathy ; congestive heart failure ; permanent pacing ; biventricular pacing ; pacing hemodynamics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Enthusiasm for permanent pacing as a therapeutic option for patients with dilated cardiomyopathy (DCM) and congestive heart failure (CHF) has waxed and waned since the early 1990‘s. The clinical results of standard dual-chamber pacing in these patients have been extraordinarily mixed, which can be attributed to small patient populations, marked heterogeneity of patients included, highly variable study designs and endpoints, and limited follow-up.  Although investigators have postulated some mechanisms for improvement, there is still a great deal to learn to be able to reliably predict which patients with DCM and/or CHF will respond to permanent pacing. Biventricular pacing is emerging as having the greatest potential for patients with congestive cardiomyopathy. Although data is somewhat limited, triple-chamber, and in some cases four-chamber pacing will be the focus of future interest.
    Notes: Zusammenfassung Die Begeisterung für das permanente Pacing als therapeutische Option bei der dilatativen Kardiomyopathie (DCM) und bei der dekompensierten Herzinsuffizienz (CHF) hat seit den frühen 90er Jahren deutlich nachgelassen. Die klinischen Ergebnisse des üblichen Zweikammer-Pacings fielen bei diesen Patienten außergewöhnlich gemischt aus. Dies kann auf kleine Patientenpopulationen, eine ausgeprägte Heterogenität der teilnehmenden Patienten, auf eine große Variabilität der Studiendesigns und Endpunkte sowie auf eine begrenzte Nachbeobachtungszeit zurückgeführt werden.  Obwohl Wissenschaftler einige Mechanismen für eine Besserung postulieren, sind viele Punkte noch offen, bis man zuverlässig voraussagen kann, welche Patienten mit DCM und/oder CHF auf ein permanentes Pacing ansprechen werden.  Es scheint so als ob das Zweikammer-Pacing das größte Potential für Patienten mit dekompensierter Herzinsuffizienz bietet. Obwohl erst limitierte Daten zur Verfügung stehen, wird in Zukunft das Dreikammer-Pacing und in manchen Fällen das Vierkammer-Pacing von Interesse sei.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s003990050043
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...